-
CanSino Biologics’ mRNA Vaccine CS-2034 Shows Positive Safety and Immunogenicity Data
•
China-based CanSino Biologics (HKG: 6185) has announced positive periodical data from a clinical study assessing the safety and immunogenicity of its COVID-19 mRNA vaccine CS-2034 as a sequential booster in adults aged 18 and above who have already received three doses of inactivated COVID-19 vaccines. The study, which began in…
-
Mindray Partners with BOMImed for Exclusive Canadian Sales and Service
•
China-based medical device giant Mindray’s North American unit has announced a partnership with Canadian biomedical firm BOMImed Inc. The deal appoints BOMImed as the exclusive sales and service provider for Mindray’s patient monitoring, anesthesia, and ultrasound solutions in Canada’s hospital market. This strategic move aims to enhance Mindray’s presence in…
-
Simnova Partners with Orna Therapeutics for In Situ CAR Therapies
•
Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has announced a partnership with Cambridge, Massachusetts-based Orna Therapeutics. The deal grants Simnova access to certain of Orna’s in situ chimeric antigen receptor (isCAR) therapies in the China market, including the CD19-targeted isCAR program ORN-101. This collaboration aims…
-
Aurisco Partners with Cytiva to Build Oligonucleotide Production Plant
•
China-based contract development and manufacturing organization (CDMO) Aurisco Pharmaceutical Co., Ltd has revealed plans to establish its first commercial-scale production plant for oligonucleotides in partnership with US-based life sciences service provider Cytiva. The new plant, located in Yangzhou, Jiangsu Province, will utilize Cytiva’s Oligo FlexFactory platform and marks the first…
-
Jiangsu Aidea’s ACC007 Approved by NMPA for HIV-1 Treatment
•
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that its Category 1 compound preparation ACC007 (ainuovirine, lamivudine, tenofovir disoproxil) has been approved by the National Medical Products Administration (NMPA) for the treatment of newly treated adult patients with HIV-1 infection. This approval marks a significant step forward in…
-
WuXi Biologics and GSK Ink Licensing Agreement for T-Cell Engaging Antibodies
•
China-based WuXi Biologics (HKG: 2269) has announced a licensing agreement with GSK plc (NYSE: GSK), granting the UK-based pharmaceutical giant exclusive licenses to up to four bi- and multi-specific T-cell engaging (TCE) antibodies. These antibodies were developed using WuXi Biologics’ proprietary technology platforms. The deal includes a pre-clinical bispecific antibody…
-
Antengene Acquires Full Rights to Calithera’s CD73 Inhibitor CB-708
•
China-based Antengene Corporation Ltd (HKG: 6996) has unveiled a transfer agreement with US-headquartered Calithera Biosciences Inc. (OTCMKTS: CALA), expanding on an earlier license agreement. Under the new agreement, Antengene will acquire all remaining rights to CB-708 (ATG-037), Calithera’s small-molecule CD73 inhibitor. This move underscores Antengene’s commitment to advancing innovative cancer…
-
Haisco’s EGFR-PROTAC HSK40118 Accepted for Review by China’s NMPA
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing for the oral small molecule EGFR-PROTAC HSK40118 has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication is EGFR mutant advanced non-small cell lung cancer (NSCLC). This marks a significant…
-
Duality Biologics Licenses ADC Platform to Denmark’s Adcendo for Mesenchymal Tumor Program
•
Duality Biologics, a developer of novel modality drugs operating in the United States and China, has announced a technology license agreement with Denmark-based Adcendo ApS. Under the agreement, Adcendo has been granted a license to use Duality’s antibody drug conjugate (ADC) platform, DITAC, in its mesenchymal tumor product uPARAP program.…
-
NMPA Strengthens Oversight of COVID-19 Drugs and Home Treatment Guidelines
•
The National Medical Products Administration (NMPA) has released a notification aimed at enhancing the quality oversight and supply security of drugs related to COVID-19 prevention and control. The guidelines focus on ensuring the quality and legal supply of common drugs listed in the “Guidelines for Home Treatment of COVID-19 Infected…
-
NMPA Approves Chinabridge’s ECMO Equipment for Emergency Use
•
The National Medical Products Administration (NMPA) has approved Chinabridge (Shenzhen) Medical Technology Co., Ltd’s extracorporeal cardiopulmonary support auxiliary equipment and disposable membrane oxygenator bag for emergency use. The combination is designed for adult patients with acute respiratory failure or acute cardiopulmonary failure, whose symptoms are difficult to control with other…
-
EOC Pharma’s Entinostat NDA Accepted by China’s NMPA for Breast Cancer
•
EOC Pharma, a biotech company operating in the US and China, has announced that its New Drug Application (NDA) filing for entinostat has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced…
-
HighTide Therapeutics Completes $107 Million Series C and C+ Financing Rounds
•
China-based HighTide Therapeutics Inc. has announced the completion of Series C and C+ financing rounds, raising a total of USD 107 million. The financing was led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital, with participation from Yuexiu Fund and Yuthai Fund. The proceeds will…
-
Biogen and Tsinghua University Launch Three-Year Neuroscience Collaboration
•
US-based Biogen (NASDAQ: BIIB) and the School of Pharmaceutical Sciences at Tsinghua University have announced a three-year strategic collaboration aimed at advancing scientific research and development in neuroscience and specialized immunology. This academic partnership marks Biogen’s first collaboration in China, highlighting the company’s commitment to expanding its research footprint in…
-
China’s NHC and NATCM Launch Integrated Pain Management Pilot Plan
•
The National Health Commission (NHC) and the National Administration of Traditional Chinese Medicine (NATCM) have released the “Integrated Pain Management Pilot Work Plan,” aimed at enhancing pain management capabilities in hospitals across China. The plan outlines a pilot program to be implemented from 2022 to 2025, focusing on exploring and…
-
Zhongchao Partners with Natco Pharma to Distribute Drugs in China
•
Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced multiple agreements with India-headquartered Natco Pharma Limited to become its distribution agent for certain drugs in mainland China. The collaboration aims to address domestic demand for influenza drugs, cancer therapies, and rare disease treatments. The two companies will…
-
By-Health to Establish Nutrition Research Center with Shanghai Institute
•
China-based By-Health Co., Ltd. (SHE: 300146) is set to establish a “scientific nutrition research and translation center” in collaboration with the Shanghai Institute of Nutrition and Health (SINH), CAS. This initiative marks a comprehensive upgrade to their existing strategic partnership. Financial details of the collaboration were not disclosed. Background and…
-
CANbridge Secures Global Rights to Second-Generation Gene Therapy for SMA
•
China – based biopharma CANbridge Pharmaceuticals Inc. (HKG: 1228) has unveiled a license deal to secure exclusive global rights to a novel, second – generation gene therapy for spinal muscular atrophy (SMA) from UMass Chan Medical School in the United States. The deal includes all development, manufacturing, and commercialization rights…
-
Transcenta’s TST003 Receives Clinical Trial Approval in China and US
•
China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received clinical trial approval in China for TST003, its potential first – in – class monoclonal antibody (mAb) targeting Gremlin1. The drug candidate has already received IND clearance from the US FDA in September this year,…
-
Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications
•
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA) has approved a supplementary Biologic License Application (sBLA) for its biosimilar Hanbeitai (bevacizumab). The approval expands the indications for which Hanbeitai can be used, now including cervical cancer, epithelial ovarian cancer, fallopian tube cancer, and…
